TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02752542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
Study: NCT02903485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurses perform presurgical assessement and surveillance during surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the anesthetic team performs presurgical assessement and surveillance during surgery
Study: NCT01680211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salacia bark extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salacia leaf extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sesame seed extract

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TLC
Description: Lifestyle changes include diet, exercise, weight loss, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC
Description: Lifestyle changes include diet, exercise, weight loss, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC
Description: Lifestyle changes include diet, exercise, weight loss, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC
Description: Lifestyle changes include diet, exercise, weight loss, etc.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04519333

Intervention type: PROCEDURE
Group type: OTHER
Intervention: drug(intradermal injection)
Description: The mesotherapy was performed by an experienced and trained physician using a disposable 4 mm and 6 mm long, 30 Gauge needles. Initially, a pharmacological mixture of 1 cc (2 mg) thiocolchicoside, 1 cc (16.2 mg) lidocaine and 1 cc (5 mg) tenoxicam was prepared for each treatment session, and 0.1-0.2 cc of this mixture was applied to each injection point with a depth of 1-3 mm using point by point intradermal method without causing papules.~In the systemic therapy group, we applied a 50 mg dexketoprofen (Revafen, Haver Pharma Pharmaceutical Co., Turkey) in 100 cc isotonic solution intravenously for 5 minutes.
Study: NCT02260037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine nasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06188611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huazhi Rougan Granule Placebo granule
Description: Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huazhi Rougan Granule Placebo granule
Description: Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
Study: NCT03146260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional TESE
Description: usual procedure for sperm extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdissection TESE
Description: Procedure of extraction is performed under the operating microscope
Study: NCT00772057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets given two times daily.
Study: NCT01676233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine- new formulation (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine- new formulation (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT02185183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alequel
Description: Alequel
Study: NCT00846157

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NKM injection
Description: NKCell about 100mg IV for 6times in each chemotherapy period.
Study: NCT01216488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine
Description: 40 ml or 25 ml of Xylocaine injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: 40 ml or 25 ml of Xylocaine injection
Study: NCT03674281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAP
Description: Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLC
Description: The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
Study: NCT02301897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate
Description: Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate
Description: Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Study: NCT01969734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zephyr endobronchial valve placement
Study: NCT02965781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SADBE
Description: Topical solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SADBE
Description: Topical solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Topical solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical solution
Study: NCT02675400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyvanse
Description: Half of the participants (fathers) will be randomized to receive Vyvanse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Half of the fathers will receive behavioral parent training.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: If Vyvanse is not well tolerated, methylphenidate can be prescribed.
Study: NCT02179034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Menthol
Description: A low dose of menthol will be added to the tobacco flavor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Menthol
Description: A low dose of menthol will be added to the tobacco flavor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose Menthol
Description: A low dose of menthol will be added to the tobacco flavor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Menthol
Description: A high dose of menthol will be added to the tobacco flavor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Menthol
Description: A high dose of menthol will be added to the tobacco flavor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Menthol
Description: A high dose of menthol will be added to the tobacco flavor.
Study: NCT01695603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent
Study: NCT03150264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV-VG, PEEP5cmH₂O
Description: This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCV, PEEP5cmH₂O
Description: This is a traditional ventilation mode used in obese patients in the past.
Study: NCT00666263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (human), 10%
Description: Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (human), 10%
Description: Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.25% human albumin solution (Placebo)
Description: Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.25% human albumin solution (Placebo)
Description: Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
Study: NCT03895034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD)
Description: Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
Study: NCT02178020

Intervention type: DEVICE
Intervention: knee arthroplasty, standard polyethylene
Description: total knee replacement follow-up; clinical and radiographic; revision rate

Intervention type: DEVICE
Intervention: knee arthroplasty, XLP polyethylene
Description: total knee arthroplasty with highly crosslinked polyethylene tibial liner
Study: NCT04870060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Lozenges
Description: Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
Study: NCT02695290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study: NCT05318885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Randomized Controlled Study
Description: For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
Study: NCT04455399

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravitreal injection guide (Malosa)
Description: A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual Blade Eyelid Speculum
Description: A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
Study: NCT02139748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant & ADM
Description: A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant & ADM
Description: A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant & ADM & bone xenograft
Description: A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
Study: NCT04633980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixture 3,6% H2 in N2 (96.4%)
Description: Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
Study: NCT00666094

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: supervised endurance training. Three sessions per week in three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: Supervised strength training. Three sessions per week in three months.
Study: NCT00328393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45 mg 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00568659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: specific elastance
Description: The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
Study: NCT04172246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib at 160 mg orally twice daily
Study: NCT00752817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proficiency-based virtual reality simulation training
Description: Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training under the current surgical training programme
Description: Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
Study: NCT02485379

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate biopsy
Description: Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy.
Study: NCT05295134

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Candida cylindracea lipase (225,000 FIP lipase units per day)
Description: Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Candida cylindracea lipase (450,000 FIP lipase units per day)
Description: Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Candida cylindracea lipase (675,000 FIP lipase units per day)
Description: Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
Study: NCT04235283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)
Description: The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary total knee replacement by traditional jig and minimally invasive technique
Description: The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
Study: NCT02715258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: tablets containing 20 mg bexagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets matching the appearance of bexagliflozin tablets
Study: NCT03439124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole medocaril
Description: Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV standard-of-care cephalosporin
Description: Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed.
Study: NCT02008019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day
Description: Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day
Description: Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
Study: NCT03498651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification - Interpretation training
Description: Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification - Interpretation training
Description: Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification - Interpretation training
Description: Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online psychoeducation about anxiety
Description: Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.